Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry

References

• Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020 Apr;92(4):401–402. DOI:10.1002/jmv.25678. PubMed PMID: 31950516. doi: 10.1002/jmv.25678
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273. DOI:10.1038/s41586-020-2012-7. PubMed PMID: 32015507; PubMed Central PMCID: PMCPMC7095418.
   PubMed Web of Science ®Google Scholar
• Organization WH. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020 2020. Available from: https://www.who.int/dg/speeches/detail/who-directorgeneral-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
   Google Scholar
• Organization WH. Coronavirus disease (COVID-19) 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034. DOI:10.1016/s0140-6736(20)30628-0.
   PubMed Web of Science ®Google Scholar
• Guy RK, DiPaola RS, Romanelli F, et al. Rapid repurposing of drugs for COVID-19. Science. 2020;368(6493):829–830. DOI:10.1126/science.abb9332. PubMed PMID: 32385101.
   PubMed Web of Science ®Google Scholar
• Guo YR CQ, Hong ZS, Tan YY, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. DOI:10.1186/s40779-020-00240-0.
   Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. DOI:10.1038/s41421-020-0156-0. PubMed PMID: 32194981; PubMed Central PMCID: PMCPMC7078228. doi: 10.1038/s41421-020-0156-0
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271. DOI:10.1038/s41422-020-0282-0. PubMed PMID: 32020029; PubMed Central PMCID: PMCPMC7054408. doi: 10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Chen W WQ, Li YQ, Yu HL, et al. Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Mar 6;54(3):239–244. DOI:10.3760/cma.j.issn.0253-9624.2020.03.003.
   PubMedGoogle Scholar
• Lai S, Ruktanonchai NW, Zhou L, et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China [published online ahead of print, 2020 May 4]. Nature. 2020. DOI:10.1038/s41586-020-2293-x. PubMed PMID: 32365354
   Web of Science ®Google Scholar
• Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;26(4):243–250. DOI:10.1007/s11655-020-3192-6. PubMed PMID: 32065348.
   PubMed Web of Science ®Google Scholar
• Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020 Apr 10;21(7):2657. DOI:10.3390/ijms21072657. PubMed PMID: 32290293; PubMed Central PMCID: PMCPMC7177898. doi: 10.3390/ijms21072657
   PubMed Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020 Apr 29;157:104859. DOI:10.1016/j.phrs.2020.104859. PubMed PMID: 32360480; PubMed Central PMCID: PMCPMC7189851. doi: 10.1016/j.phrs.2020.104859
   PubMed Web of Science ®Google Scholar
• Kierzek G, Rac V, Pourriat JL. Is emergency research without initial consent justified? The consent substitute model. Arch Intern Med. 2010 Sep 13;170(16):1508–1509. ; author reply 1509. DOI:10.1001/archinternmed.2010.295. PubMed PMID: 20837844.
   PubMedGoogle Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 May 7;382(19):1787–1799. DOI:10.1056/NEJMoa2001282. PubMed PMID: 32187464; PubMed Central PMCID: PMCPMC7121492. doi: 10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Edwards KM, Kochhar S. Ethics of Conducting Clinical Research in an Outbreak Setting [published online ahead of print, 2020 Mar 25]. Annu Rev Virol. 2020. doi: 10.1146/annurev-virology-013120-013123
   PubMed Web of Science ®Google Scholar
• Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med. 2020 Jun 15;e202250. DOI:10.1001/jamainternmed.2020.2250. PubMed PMID: 32539071; PubMed Central PMCID: PMCPMC7296449.
   PubMed Web of Science ®Google Scholar
• Nasrallah AA, Farran SH, Nasrallah ZA, et al. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. J Clin Epidemiol. 2020 Jun 8;S0895-4356(20)30441-8. DOI:10.1016/j.jclinepi.2020.06.005. PubMed PMID: 32526460; PubMed Central PMCID: PMCPMC7278640.
   PubMed Web of Science ®Google Scholar
• Wang S, Zeng X, Wang Y, et al. East meets West in COVID-19 therapeutics. Pharmacol Res. 2020 Jun 9;159:105008. DOI:10.1016/j.phrs.2020.105008.
   Web of Science ®Google Scholar
• Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial [published online ahead of print, 2020 May 16]. Phytomedicine. 2020;153242. DOI:10.1016/j.phymed.2020.153242.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473–475. DOI:10.1016/s0140-6736(20)30317-2.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Coronavirus (COVID-19) Update: Daily Roundup March 30. (2020). US Food and Drug Administration. 2020.
   Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Br Med J. 2020 May 14;369:m1849. DOI:10.1136/bmj.m1849. PubMed PMID: 32409561; PubMed Central PMCID: PMCPMC7221473 at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work other than those listed above; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020 May 30;395(10238):1695–1704. DOI:10.1016/s0140-6736(20)31042-4.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020. DOI:10.1056/NEJMoa2015301. PubMed PMID: 32459919.
   Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020 Jun 11;382(24):2327–2336. DOI:10.1056/NEJMoa2007016.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020 May 16;395(10236):1569–1578. DOI:10.1016/s0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):542–544. DOI:10.1080/22221751.2020.1737580.
   PubMed Web of Science ®Google Scholar
• Organization WH. DRAFT landscape of COVID-19 candidate vaccines -15 May 2020 2020. Available from: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020;395(10239):1751–1752. DOI:10.1016/s0140-6736(20)31252-6.
   PubMed Web of Science ®Google Scholar